A protective effect of epidermal powder immunization in a mouse model of equine herpesvirus-1 infection  by Kondo, Takashi et al.
www.elsevier.com/locate/yviro
Virology 318 (2004) 414–419A protective effect of epidermal powder immunization in a mouse model
of equine herpesvirus-1 infection
Takashi Kondo,a,b Martha McGregor,b Qili Chu,c Dexiang Chen,c
Taisuke Horimoto,d,e and Yoshihiro Kawaokab,d,e,*
aEpizootic Research Station, Japan Racing Association, Equine Research Institute, Tochigi 329-0412, Japan
bDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
cPowderJect Vaccines, Inc., Madison, WI 53711, USA
dDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan
eCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Saitama 332-0012, JapanReceived 18 August 2003; returned to author for revision 22 September 2003; accepted 25 September 2003Abstract
To evaluate the protective effect of epidermal powder immunization (EPI) against equine herpesvirus-1 (EHV-1) infection, we prepared a
powder vaccine in which formalin-inactivated virions were embedded in water-soluble, sugar-based particles. A PowderJect device was used
to immunize mice with the powder vaccine via their abdominal skin. We found that twice-immunized mice were protected against challenge
with the wild-type virus. This protective effect was equivalent to or better than that observed in mice immunized with other types of vaccines,
including a gene gun-mediated DNA vaccine containing the glycoprotein D (gD) gene or conventional inactivated virus vaccines introduced
via intramuscular or intranasal injections. These findings indicate that the powder vaccine is a promising approach for the immunological
control of EHV-1 infection, either alone or as a part of prime-boost vaccination strategies.
D 2003 Elsevier Inc. All rights reserved.Keywords: Equine herpesvirus-1; Epidermal powder immunization; VaccineIntroduction
Equine herpesvirus-1 (EHV-1), which causes respiratory
diseases, abortion, occasional neurological signs, and neo-
natal mortality, is enzootic in horses worldwide and a
significant economic burden to the horse industry (Allen
and Bryans, 1986; Crabb and Studdert, 1995). As with other
herpesvirus infections, lifelong latency of the virus in the
nervous system of the host occurs, and periodical reactiva-
tion of the virus can cause new outbreaks (Slater et al.,
1994).
Because EHV-1 initiates its infection from the mucosal
surface, a combination of mucosal and systemic antibody
and cytotoxic T-lymphocyte (CTL) responses is required for
successful immunological control of EHV-1 infection (Allen
et al., 1999). Inactivated virus vaccines, which have been0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: kawaoka@ims.u-tokyo.ac.jp (Y. Kawaoka).widely used for EHV-1 infection, are known to render only
limited efficacy (Burrows et al., 1984; Gilkerson et al.,
1997). Therefore, the development of more efficacious
vaccines is essential to protect animals from both primary
and reactivated EHV-1 infections. One approach has been
DNA vaccination with glycoprotein (gp)-coding sequences
because of its potential to induce both humoral and cell-
mediated immunities (Fynan et al., 1993). Intramuscular
(i.m.) inoculation of mice with glycoprotein D (gD) DNA
has been shown to protect them from challenge with wild-
type viruses and to induce higher levels of gD-specific
antibodies in horses with pre-existing EHV-1/-4 antibody
(Ruitenberg et al., 2000a). Moreover, a prime-boost immu-
nization strategy of inoculation with gD DNA followed by
purified gD protein has been shown to enhance both
humoral and cell-mediated immune responses (Ruitenberg
et al., 2000b).
Another promising technique is epidermal powder im-
munization (EPI). EPI is a new approach that delivers DNA
or antigens via a needle-free delivery system directly to the
epidermis, where Langerhans cells with antigen-processing
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2002). EPI is highly effective in inducing immune responses
to viral agents, such as influenza, hepatitis B, and human
immunodeficiency viruses (Chen et al., 2000, 2001a, 2001c,
2002a, 2002b; Osorio et al., 2003). In addition, EPI does not
cause pain, injection-site reactions, or any severe adverse
effects at the site of administration because of the low level
of sensory nerve endings and vasculature in the epidermis.
In this study, we compared the protective efficacy of whole
virus-based EPI with that of a powdered gD DNA vaccine
and that of inactivated virus vaccines introduced by i.m. or
intranasal (i.n.) injection in a mouse model of EHV-1
infection, which mimics many of the features of infection
in the natural host (Awan et al., 1990; Walker et al., 1999).Fig. 1. Antibody responses to epidermal immunizations. A powder vaccine
was prepared from whole virus and used to immunize BALB/cBYJ mice
once (Single) or twice (Boosted) with either 0.5 or 5.0 Ag of virus by use of
a PowderJect device. A DNA vaccine was prepared from a plasmid
expressing gD (1.0 Ag) and used to immunize BALB/cBYJ mice once
(Single) or twice (Boosted) by use of a gene delivery system. Sugar only- or
vector alone-inoculated mice were used as controls (Cont.) for the powder
or DNA vaccines, respectively. Sera were collected for ELISA titration of
specific antibodies from immunized mice before challenge with the wild-
type virus. The P values (Student t test) are shown as *P < 0.05, **P <
0.01, ***P < 0.001, or ns (not significant).Results and discussion
Protective effect of a powder vaccine
Two doses of a powder vaccine (0.5 or 5 Ag per mouse)
were delivered to the abdominal skin of mice using a
PowderJect device. A powder formulation that lacked the
virus components was used as control. The test and control
groups each consisted of 12 mice; in each group, six mice
were immunized either once or twice after a 4-week interval.
The six mice given a single immunization were then
challenged with a wild-type virus (5 107 PFU/50 Al) i.n.
4 weeks after immunization. The six mice immunized twice
were challenged with the same amount of the wild-type
virus 2 weeks after the second immunization. Four days
post-challenge, mice were euthanized and their lungs re-
moved for virus titrations to evaluate the protective efficacy
of the vaccine.
Before the challenge, the serum antibody response of
each vaccinated mouse was measured by using an enzyme-
linked immunosorbent assay (ELISA) with purified virus as
an antigen. Significant induction of virus-specific IgG anti-
bodies was detected irrespective of vaccine doses, even
following the single immunization (Fig. 1). Post-challenge,
the virus titers in the lungs were significantly reduced in the
immunized mice compared with the titers in the lungs of the
mock-immunized, control mice (Fig. 2). The booster immu-
nization enhanced these protective effects. There was no
significant difference in the efficacy between the two
vaccine doses (0.5 vs. 5 Ag). These results together indicate
that the powder vaccine is effective against EHV-1 infection
in this mouse model and provide the first evidence of
effective EPI for herpesvirus infection.
Protective effect of a DNA vaccine
For comparison, we then prepared a DNA vaccine for
epidermal immunization with a gene gun (Fynan et al.,
1993). We constructed three gp-expression plasmids
(pCEHV-1 gB, pCEHV-1 gC, and pCEHV-1 gD) andconfirmed protein expression by transfecting each plasmid
into COS-1 cells and immunostaining those cells with
monoclonal antibodies to the gps. All three gps were
expressed in the transfected cells (data not shown).
We next assessed the immunogenicity of gene gun-based
DNA vaccination, the effectiveness of which has not previ-
ously been reported for EHV-1 infection. Previous studies
have shown that gB, gC, and gD proteins are immunogenic,
eliciting both neutralizing antibodies and cell-mediated
immunity (cytotoxic T lymphocytes) (Alber et al., 2001;
Packiarajah et al., 1998; Ruitenberg et al., 2001; Stokes et
al., 1997; Tewari et al., 1994, 1995). To assess which gp-
encoding DNA was the most immunogenic in our gene gun
system, we injected mice with each DNA construct (1 Ag)
twice at a 2-week interval. Two weeks after the second
injection, serum neutralizing antibody titers were measured
by plaque-reduction assays. The sera from mice injected
with pCEHV-1 gD contained specific neutralizing antibod-
ies in agreement with previous reports (Ruitenberg et al.,
1999; Walker et al., 2000); however, the sera from mice
injected with pCEHV-1 gB and gC did not contain specific
neutralizing antibodies (data not shown). For this reason, we
used only the gD DNA vaccine for our further experiments.
To evaluate the protective effect of the gD DNA vaccine,
we delivered pCEHV-1 gD (1 Ag) to the abdominal skin of
mice with a gene gun. As a control, plasmid vector was
similarly delivered. Each group (test and control) consisted
of 12 mice. Significant induction of a specific IgG antibody
was not observed with a single immunization (Fig. 1), and
in keeping with this finding, a single immunization did not
protect the mice from challenge with the wild-type virus.
Fig. 2. Protective efficacy of epidermal immunizations against EHV-1
infection in mice. Preparation and immunization protocols of powdered
inactivated and DNA vaccines were as described in the legend for Fig. 1.
Lungs were removed 4 days post-challenge with the wild-type virus, and
homogenates were titrated for virus. The P values (t test) are shown at the
top, as in Fig. 1.
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significantly reduced compared with the control (Fig. 2). By
contrast, no virus was recovered from the lungs of any mice
given the booster immunization, which suggests that the
vaccine can be effective under the right conditions and
corroborates previous studies of i.m. injection of gD DNA
(Ruitenberg et al., 1999; Walker et al., 2000). These data
indicate that gene gun-mediated DNA epidermal immuni-
zation for EHV-1 infection may be useful; however, the
failure of this approach to protect mice given a single
immunization suggests that the protein-based epidermal
immunization with the powder vaccine may be more effec-
tive than DNA-based epidermal immunization.Fig. 3. Antibody responses to whole virus vaccines. A powdered inactivated vacc
were prepared from whole virus and BALB/cBYJ mice were immunized once or tw
virus. Untreated mice served as controls (Cont.). ELISAwas done as described inProtective effect of an inactivated vaccine
To compare the efficacy between protein-based vaccines,
we next examined the protective efficacy of the traditionally
inactivated virus vaccines. Vaccines were administrated
once (single) or twice (boosted) via the i.m. route with
Freund’s complete adjuvant (FCA) or via the i.n. route
dosed at 0.5 or 5 Ag per mouse. Four weeks after the
primary immunization, six mice in each group were given
booster immunization under the same conditions as before.
Before virus challenge, the serum IgG antibody responses
were significantly higher in mice immunized i.m. with the
inactivated vaccine than those epidermally immunized with
the powdered inactivated vaccine (Fig. 3). However, no
significant differences in protection were observed between
these two vaccination strategies, with the exception of one
experimental condition where mice received a lower dose of
the vaccine twice (Fig. 4). These results suggest that the
powdered inactivated vaccine may induce better CTL
responses to the viral antigens than those induced by
inactivated vaccines. Together, these data suggest that the
powdered inactivated vaccine is at least as efficacious as
inactivated vaccines in protecting against EHV-1 infection.
Live, attenuated vaccines offer another option for the
control of EHV-1 infection. Commercial live, attenuated
vaccines and vaccine candidates include tissue culture-
selected thymidine kinase-deficient, temperature-sensitive,
and gE/gI-deficient viruses (Bu¨rki et al., 1990; Cornick et
al., 1990; Matsumura et al., 1998; Patel et al., 2003a, 2003b;
Slater et al., 1993). Their protective efficacies appear to vary
depending on the experimental conditions. Of these vac-
cines, the recently developed vaccine candidate derived
from a temperature-sensitive mutant showed remarkable
efficacy for protection against abortion and respiratory
318 (2004) 414–419ine was prepared as described in the legend for Fig. 1. Inactivated vaccines
ice, intramuscularly (i.m.) or intranasally (i.n.), with either 0.5 or 5.0 Ag of
the legend for Fig. 1. The P values (t test) are shown at the top, as in Fig. 1.
Fig. 4. Protective efficacy of whole virus vaccines against EHV-1 infection in mice. The powder and the inactivated vaccines were prepared as described in the
legends for Figs. 1 and 3. Challenge with the wild-type virus and virus titration protocols were as described in the legend for Fig. 2. The P values (t test) are
shown at the top, as in Fig. 1.
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Although long-term immunity might be anticipated by these
live vaccines, the possibility of a vaccine virus regaining its
virulence and causing persistent infection is a major con-
cern. Therefore, extensive safety evaluation is required for
live vaccines.
Because a combination of mucosal and systemic anti-
body and CTL responses is thought to be required for
successful immunologic control of EHV-1 infection (Allen
et al., 1999), a single type of vaccine alone may not be
sufficient to achieve such control. Accordingly, combined
vaccinations involving prime-boost strategies may be more
effective, as exemplified by the study of Ruitenberg et al.
(2000b), in which they showed that a combination of gD-
based DNA and purified gD protein immunizations could
enhance virus-specific antibody titers relative to those
achieved in mice immunized with DNA or protein only.
Although the titers of virus-specific serum IgG were higher
in mice administrated inactivated vaccine via i.m. than via
i.n. (Fig. 3), both provided equivalent protective effects
(Fig. 4), suggesting the induction of mucosal IgA antibody
by i.n. immunization of the inactivated vaccine. Given that
EPI induces CTL and humoral responses (Chen et al.,
2001a), a prime-boost vaccination with i.n.-inactivated
vaccine (for the mucosal immune response) and EPI (for
both humoral and cellular immune responses) may be more
effective in preventing EHV-1 infection. Moreover, using
adjuvants (such as alum, inactivated cholera toxin, or CpG
DNA) or coating gold particles with antigens can enhance
both the CTL and antibody responses of powder vaccines to
some virus infections (Chen et al., 2001b; Maa et al., 2003).
Thus, it would be of interest to test whether such adjuvants
enhance the efficacy of the EHV-1 powdered inactivated
vaccine and to assess which prime-boost combinations
(among powdered inactivated, DNA, and inactivated vac-cines) are the most effective for the prevention and control
of EHV-1 infection.Materials and methods
Cells and virus
Equine derm cells, Madin –Darby bovine kidney
(MDBK) cells, and COS-1 cells were cultured in Eagle’s
minimum essential medium (MEM) supplemented with
10% fetal calf serum (FCS) and antibiotics. EHV-1, strain
89 c25 (Matsumura et al., 1998), was used for all experi-
ments. Virus-infected cells were maintained in MEM with
2% FCS for 4 days.
Preparation of and immunization with a powder vaccine
Virus, propagated in equine derm cells, was concentrated
by centrifugation (100,000  g), resuspended in TNE buffer
(20 mM Tris–HCl, pH 7.4, 0.14 M NaCl, 1 mM EDTA),
and purified through a 20–60% (w/v) sucrose gradient.
Virus-containing fractions were pelleted, resuspended in
20 mM phosphate buffer, and inactivated with formalin.
Briefly, formalin (0.01%) was added in equal volume to the
virus suspension and samples were incubated at 4 jC for 72
h, then subjected to four cycles of freeze (in liquid nitro-
gen)-and-thaw (at 37 jC). Inactivation of the virus was
confirmed by plaque assay with MDBK cells. To create a
sugar-based powder vaccine, D(+)-trehalose (Sigma) was
added to the inactivated virus preparation to a final concen-
tration of 20% (w/v). This sugar–virus mixture was then
spread by droplets onto a glass petri dish, dried in a
desiccator for 48 h, scraped from the plates, and sieved to
make particles of 35–38 nm in diameter. This formulation
T. Kondo et al. / Virology 318 (2004) 414–419418was stored under desiccation at 4 jC. For the PowderJect
ND device (PowderJect Vaccines), the powder vaccine (1
mg; containing 5 or 0.5 Ag of virus components) was loaded
into a trilaminate cassette, sealed with membrane, and stored
in a desiccator until use.
We used BALB/cBYJ mice (5-week-old female) to
evaluate the protective effect of the powder vaccine. After
the hair on the abdomen of these mice was shaved, the
powder vaccine (0.5 or 5 Ag per mouse) was delivered to the
abdominal skin by use of the PowderJect device with helium
(He) gas at a pressure of 50 bar.
Preparation and immunization of DNA vaccines
The full-length gB, gC, and gD genes were amplified by
PCR from EHV-1 (strain 89 c25)-infected cells and cloned
into the pCAGGS/MCS plasmid (Kobasa et al., 1997; Niwa
et al., 1991) (designated pCEHV-1 gB, pCEHV-1 gC, and
pCEHV-1 gD, respectively). All constructs were sequenced;
the nucleotide sequences of these gps were identical to those
of strain Ab4 in GenBank, except for one silent substitution
in the gC gene. The sequence of the PCR and sequencing
primers will be provided upon request. For immunization
with the PowderJect XR delivery system (PowderJect Vac-
cines), the gp plasmids and the vector alone (included as a
control) were purified with a commercial kit (QIAGEN),
combined with gold beads in 0.05 M spermidine by soni-
cation, washed three times with 100% ethanol, and then
resuspended in ethanol. The adhesive 0.1% PVP (in ethanol)
was then added and the DNA-gold bead suspension was
placed in tefzel tubing in a tube turner and dried in nitrogen
gas. The tubes were cut into cartridge-size sections and
stored in a desiccator at 4 jC until use. To determine the
amount of DNA on the beads, a small amount of TE buffer
was placed in the cartridges and shaken for 10 min. The
buffer was then centrifuged to deposit the beads and the
supernatant run on an agarose gel; the plasmid DNA
concentration was 1 Ag per cartridge. To investigate the
immunogenicity of the DNA vaccines, we delivered gp-
expression plasmids (1 Ag) to the abdominal skin of mice
with a gene gun at 400 psi He gas pressure.
Immunization with an inactivated vaccine
The formalin-inactivated purified virus, used for the
powder vaccine, was also used for an inactivated virus
vaccine. The vaccine was administrated via the i.m. route
with Freund’s complete adjuvant (FCA) or via the i.n. route
dosed at 0.5 or 5 Ag per mouse.
Detection of virus-specific antibodies
Blood was taken via retro-orbital bleeding under anes-
thesia from each vaccinated mouse and the serum antibody
response measured by ELISA with purified virus as an
antigen. Briefly, Immulon II plates (Thermo Labosystems)were coated with purified virus (0.5 Ag/well) in PBS. Plates
were blocked with 5% skim milk for 1 h and washed three
times with PBS–0.05% Tween 20. Mouse sera dilutions (50
Al) were then added to each well and incubated for 1 h. Plates
were then washed three times and 50 Al of conjugate (goat
anti-mouse Ig horseradish peroxidase) (Zymed; 1:5,000) was
added and incubated for 1 h. Plates were then washed three
times and 100 Al of substrate (ABTS) was added for 15 min.
Color development was stopped with 1% NaF and absor-
bance was read (optical density at 405-nm wavelength). The
highest dilution of test sera to yield an absorbance of 0.1
units higher than that of the control normal mouse serum was
considered to be the virus-specific titer.
Challenge with a wild-type virus
Mice were immunized once with each vaccine and
challenged with 5  107 PFU of wild-type virus (in 50
Al) i.n. 4 weeks after immunization. Mice immunized twice
were challenged with the same amount of wild-type virus 2
weeks after the second immunization. Four days post-
challenge, virus titers in lung homogenates from the mice
were determined by using plaque assays with MDBK cells.Acknowledgments
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